Posted inCardiology Internal Medicine news
Aggressive LDL-C Lowering Mitigates Neoatherosclerosis Risk: Insights from the CONNECT Trial
This secondary analysis of the CONNECT trial demonstrates that achieving guideline-endorsed LDL-C levels significantly lowers the risk of neoatherosclerosis three years post-DES implantation in STEMI patients, underscoring the vital role of aggressive lipid management in secondary prevention.
